Altimmune, Inc. (NASDAQ:ALT – Get Free Report) Director Wayne Pisano purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, November 13th. The shares were acquired at an average cost of $1.64 per share, for a total transaction of $16,400.00. Following the purchase, the director owned 58,800 shares of the company’s stock, valued at $96,432. This represents a 20.49% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Altimmune Price Performance
ALT stock opened at $1.65 on Monday. Altimmune, Inc. has a 52 week low of $1.58 and a 52 week high of $6.44. The company has a quick ratio of 23.93, a current ratio of 23.93 and a debt-to-equity ratio of 0.08. The company has a fifty day simple moving average of $2.58 and a two-hundred day simple moving average of $3.15. The firm has a market capitalization of $319.98 million, a P/E ratio of -2.28 and a beta of 0.16.
Altimmune (NASDAQ:ALT – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Analysts anticipate that Altimmune, Inc. will post -0.58 earnings per share for the current fiscal year.
Altimmune News Roundup
These are some of the ALT news items that stood out recently:
- Neutral Sentiment: B. Riley reaffirmed its Buy rating, providing supportive analyst sentiment, although the rating is not a guarantee of future performance.
- Negative Sentiment: Third-quarter loss per share was $0.15, wider than the $0.13 loss analysts expected. Higher research and development spending contributed to the miss, and commentary has raised concerns about the company’s capital needs despite its current cash runway. Earnings analysis
- Negative Sentiment: A Seeking Alpha analysis characterized pemvidutide’s development as late and capital-intensive, underscoring the risk that lengthy trials and spending could weigh on ALT before any potential product revenue. Analysis
Analysts Set New Price Targets
Several research firms recently commented on ALT. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research report on Friday. Wall Street Zen downgraded Altimmune from a “sell” rating to a “strong sell” rating in a research report on Saturday. B. Riley Financial restated a “buy” rating on shares of Altimmune in a research report on Friday. Evercore reaffirmed an “outperform” rating on shares of Altimmune in a research note on Wednesday, September 23rd. Finally, HC Wainwright reiterated a “buy” rating on shares of Altimmune in a report on Tuesday, July 28th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.33.
View Our Latest Stock Report on ALT
Hedge Funds Weigh In On Altimmune
Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP lifted its holdings in Altimmune by 268.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock valued at $3,221,000 after buying an additional 762,223 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Altimmune in the 2nd quarter valued at about $2,097,000. Hennion & Walsh Asset Management Inc. boosted its position in Altimmune by 156.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock valued at $1,575,000 after buying an additional 316,209 shares during the period. Nantahala Capital Management LLC grew its stake in Altimmune by 14.7% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,720,000 shares of the company’s stock worth $4,919,000 after acquiring an additional 220,000 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Altimmune by 48.6% in the 1st quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock worth $1,756,000 after acquiring an additional 186,420 shares in the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.
About Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
Featured Articles
- Five stocks we like better than Altimmune
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
